Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
Status:
Completed
Trial end date:
2020-09-29
Target enrollment:
Participant gender:
Summary
This study is looking at the effects of giving early treatment of deferiprone to young
children with beta thalassemia who have started receiving regular blood transfusions but have
not yet reached the criteria for starting on iron chelation therapy. Half the patients in the
study will receive deferiprone, and the other half will receive placebo, for up to 12 months.